Jefferies Downgrades Ford Motor to Hold, Announces $25 Price Target

Jefferies analyst Philippe Houchois downgrades Ford Motor (NYSE:F) from Buy to Hold and announces $25 price target.

byBenzinga Newsdesk

January 20, 2022

1 minute read

Jefferies analyst Philippe Houchois downgrades Ford Motor (NYSE:F) from Buy to Hold and announces $25 price target.

Cathie Wood Adds $11M In Tesla With Stock Pile-Up Nearing Half A Million Mark Just 2 Weeks Into 2023

By Bhavik Nair

Today, 3:20 AM

Cathie Wood-led ARK Investment Management continued to load up on Tesla Inc (NASDAQ: TSLA) stock for the f

ARKK

Bitcoin, Ethereum Edge Higher, Dogecoin Slips: Analyst Says Apex Coin Fundamentals ‘Still Support Healthy Consolidation’

By Shivdeep Dhaliwal

Today, 3:20 AM

Major coins traded slightly higher on Wednesday evening, even as the global cryptocurrency market cap fell 0.6% to $963.8 billion at 8:27 p.m. EDT.

$DOGE

M.D.C. Holdings Q2 EPS $2.59 Beats $2.50 Estimate

By Benzinga Newsdesk

Today, 3:20 AM

M.D.C. Holdings (NYSE:MDC) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.50 by 3.6 percent. This is a 22.75 percent increase over earnings of $2.11 per share from the same

MDC

PureTech Health Reports Imbrium Therapeutics Exercised License Option Under R&D Collab For LYT-503/IMB-150 For Interstitial Cystitis/Bladder Pain Syndrome; PureTech Receives $6.5M, Is Eligible For Added $53M In Milestones

By Benzinga Newsdesk

Today, 3:20 AM

Imbrium Therapeutics has paid PureTech $6.5 million and PureTech is eligible to receive up to $53 million in additional development milestone payments for this program in addition to royalties on product sales Imbrium

PRTC

Jefferies Downgrades Ford Motor to Hold, Announces $25 Price Target

Related Posts

Cathie Wood Adds $11M In Tesla With Stock Pile-Up Nearing Half A Million Mark Just 2 Weeks Into 2023

Bitcoin, Ethereum Edge Higher, Dogecoin Slips: Analyst Says Apex Coin Fundamentals ‘Still Support Healthy Consolidation’

M.D.C. Holdings Q2 EPS $2.59 Beats $2.50 Estimate

PureTech Health Reports Imbrium Therapeutics Exercised License Option Under R&D Collab For LYT-503/IMB-150 For Interstitial Cystitis/Bladder Pain Syndrome; PureTech Receives $6.5M, Is Eligible For Added $53M In Milestones